Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Level 3 Reconciliation) (Details)

v2.4.1.9
Fair Value Measurements (Level 3 Reconciliation) (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Mar. 31, 2015
Assets:  
Fair value of level 3 financial instrument assets as of December 31, 2014 $ 322us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
Assumed payments made by Pfizer or assignee (297)us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
Fair value adjustments to co-promote termination liability 63lgnd_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetFairValueAdjustment
Fair value of level 3 financial instrument assets as of March 31, 2015 88us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
Liabilities:  
Fair value of level 3 financial instrument liabilities as of December 31, 2014 11,819us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
Assumed payments made by Pfizer or assignee (297)us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
Payments to CVR and other former license holders (3,246)us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
Fair value adjustments to contingent liabilities 1,159lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities
Fair value adjustments to co-promote termination liability 63lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentCoPromotionTermination
Fair value of level 3 financial instrument liabilities as of March 31, 2015 $ 9,498us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue